Malarone (Atovaquone/Proguanil)
Atovaquone and proguanil hydrochloride
Brand names:Malarone, Malarone Pediatric
A fixed-combination antimalarial of atovaquone and proguanil used for prevention and treatment of Plasmodium falciparum malaria in deployment to endemic regions. Malarone is the preferred prophylactic antimalarial for many US military deployments due to its tolerability profile and once-daily dosing.
Pharmacology and Actions
Atovaquone selectively inhibits the parasite mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting ATP production and pyrimidine biosynthesis in Plasmodium. Proguanil is metabolized to cycloguanil, which inhibits parasite dihydrofolate reductase. The combination has synergistic activity against erythrocytic and pre-erythrocytic (liver stage) parasites, providing both causal prophylaxis and treatment activity. The drug is active against chloroquine-resistant P. falciparum.
Indications
- Malaria prophylaxis in travelers and military personnel to endemic regions
- Treatment of acute uncomplicated Plasmodium falciparum malaria
- Alternative prophylaxis for individuals intolerant of mefloquine or doxycycline
- Pre-deployment and post-deployment malaria prevention per CDC and military guidance
Absolute Contraindications
- Known atovaquone or proguanil allergy
- Severe renal impairment (creatinine clearance below 30 mL/min)
- Pregnancy (relative; risk-benefit consideration)
Precautions and Side Effects
Generally well tolerated compared to other antimalarials. Common adverse effects include nausea, abdominal pain, vomiting, headache, and elevated liver enzymes. Severe adverse effects are uncommon but include Stevens-Johnson syndrome and anaphylaxis. Take with food or milky drink to enhance absorption (food increases atovaquone absorption by approximately 3-fold). Diarrhea can reduce absorption and efficacy.
Adult Dosing
Pediatric Dosing
Pediatric dosing by weight using pediatric tablets (62.5 mg atovaquone/25 mg proguanil): 5 to 8 kg, half pediatric tablet daily; 9 to 10 kg, three-quarter pediatric tablet daily; 11 to 20 kg, one pediatric tablet daily; 21 to 30 kg, two pediatric tablets daily; 31 to 40 kg, three pediatric tablets daily; over 40 kg, one adult tablet daily.
Pharmacokinetics
Peak Effect: PO: 2 to 8 hours after dose with food
Duration: Half-life 2 to 3 days; supports once-daily dosing
Storage and Handling
Store tablets at controlled room temperature (15 to 30 degrees Celsius). Protect from moisture and light.
Reconstitution:
Tablets require no reconstitution.
TCCC and TECC Role
Malarone is not a wound or trauma management agent in TCCC but is essential to deployment medicine for any operation in malaria-endemic regions. The drug is one of three CDC-recommended prophylactic agents (alongside doxycycline and mefloquine) and is preferred by many US military units due to tolerability and the simple causal-prophylaxis dosing schedule (1 day before, daily during, 7 days after departure from endemic area). For non-deployment-medicine kits this drug is not typically carried.
Malarone is the antimalarial that earns its place in deployment kits because team members will actually take it. Compared to mefloquine (Lariam) with its neuropsychiatric concerns and doxycycline with photosensitivity and esophagitis risks, Malarone has a tolerability advantage that translates to better compliance. The cost is higher per dose, but the abbreviated post-travel course (7 days vs 4 weeks for doxycycline and mefloquine) reduces total medication exposure. Take with food. The other consideration is that resistance to Malarone has emerged in some regions; verify regional susceptibility through current CDC or military medical intelligence before deployment.
Stopping Malarone too early after returning from an endemic region. The 7-day post-travel course is critical to eliminate any pre-erythrocytic parasites; stopping at the end of travel risks breakthrough malaria. The other common error is taking Malarone on an empty stomach, which substantially reduces atovaquone absorption and prophylactic efficacy.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Malarone (Atovaquone/Proguanil)
| PO | Prophylaxis: 1 adult tablet (250 mg atovaquone/100 mg proguanil) PO once daily, starting 1 to 2 days before travel to endemic area, continuing through travel, and for 7 days after leaving the endemic area. Treatment of uncomplicated P. falciparum malaria: 4 adult tablets PO once daily for 3 consecutive days. (Prophylactic effect achieved within 1 to 2 days of starting; clinically relevant onset for treatment within hours) |